Although the Tyk-2 inhibitor, deucravacitinib, showed promise in a recent phase II trial [71], the concern of thromboembolism and cancer risk in post-marketing studies of RA, particularly in older patients with a cardiovascular risk [72], has led to caution of the use of Jakinibs in patients with SLE, who are at augmented risk of malignancy and premature atherosclerosis. This evidence concerns the gene TYK2 and cancer.